We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Oral Bacteria May Cause Colorectal Cancer

By LabMedica International staff writers
Posted on 27 Aug 2013
Gut microbes have been linked to colorectal cancer, but it still unclear whether and how they might cause tumors to form in the first place.

Bacteria found in the mouth, known as Fusobacterium, stimulate poor immune responses, and turn on cancer growth genes to generate colorectal tumors; data, which could lead to more effective strategies for the early diagnosis, prevention, and treatment of colorectal cancer.

Image: Blood agar plate showing colonies of Fusobacterium nucleatum (Photo courtesy of US National Library of Medicine).
Image: Blood agar plate showing colonies of Fusobacterium nucleatum (Photo courtesy of US National Library of Medicine).

In recent studies, teams of scientists at the Dana-Farber Cancer Institute (Boston, MA, USA) found that Fusobacterium are prevalent in human adenomas, which are benign tumors that can become malignant over time, suggesting that these bacteria contribute to early stages of tumor formation. These bacteria accelerated the formation of tumors by attracting immune cells called myeloid cells, which invade tumors and stimulate inflammatory responses that can cause cancer.

In a separate study, scientists at the Case Western Reserve University (Cleveland, OH, USA) discovered that Fusobacterium nucleatum rely on a molecule called Fusobacterium adhesin A (FadA), which is found on the surface of these bacterial cells, to attach to and invade human colorectal cancer cells. FadA then turns on cancer growth genes, stimulates inflammatory responses in these cells, and promotes tumor formation. The FadA levels were much higher in tissues from patients with adenomas and colorectal cancer compared with healthy individuals. They also identified a compound that can prevent FadA's effects on cancer cells.

Wendy S. Garrett, MD, PhD, one of the senior authors, said, “Fusobacterium may provide not only a new way to group or describe colon cancers but also, more importantly, a new perspective on how to target pathways to halt tumor growth and spread." The authors concluded that unlike other bacteria linked to colorectal carcinoma, F. nucleatum does not exacerbate colitis, enteritis, or inflammation-associated intestinal carcinogenesis. However, their data suggest that, through recruitment of tumor-infiltrating immune cells, Fusobacterium generate a proinflammatory microenvironment that is conducive for colorectal neoplasia progression. The studies were published on August 14, 2013, in the journal Cell Host & Microbe.

Related Links:

Dana-Farber Cancer Institute
Case Western Reserve University



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA

Latest Immunology News

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
27 Aug 2013  |   Immunology

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
27 Aug 2013  |   Immunology

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment
27 Aug 2013  |   Immunology



PURITAN MEDICAL